LB
Lusis Biosciences supplies molecular biology reagents and next‑generation qPCR instruments to research and clinical laboratories worldwide. Its VeraPoint reagent line targets infectious‑disease assays, while the Q‑Vera platform delivers high‑throughput quantitative PCR with integrated data analysis. The company monetizes through direct product sales and offers included concierge‑level technical support to reduce operational costs and accelerate test turnaround for its customers.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Lusis Biosciences supplies high‑performance molecular reagents and next‑generation qPCR instruments for infectious disease testing. Their integrated development and manufacturing platform enables a broad catalog of ready‑made assays, reducing cost and turnaround time for laboratories. The company also provides dedicated customer support and field application scientists to ensure reliable implementation and results.